AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Company Description
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer.
The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL).
Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others.
The company was incorporated in 2018 and is headquartered in Dallas, Texas.
Country | United States |
IPO Date | Mar 19, 2021 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 49 |
CEO | Bronson Crouch |
Contact Details
Address: 3963 Maple Avenue Dallas, Texas United States | |
Website | https://instilbio.com |
Stock Details
Ticker Symbol | TIL |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001789769 |
CUSIP Number | 45783C101 |
ISIN Number | US45783C2008 |
Employer ID | 83-2072195 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Bronson Crouch | Chairman & Chief Executive Officer |
Dr. Sandeep Laumas M.D. | Chief Financial Officer & Chief Business Officer |
Dr. Mark E. Dudley Ph.D. | Chief Scientific Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jan 14, 2025 | 8-K | Current Report |
Dec 23, 2024 | 8-K | Current Report |
Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Nov 13, 2024 | S-3 | Filing |
Nov 13, 2024 | 10-Q | Quarterly Report |
Nov 13, 2024 | 8-K | Current Report |
Oct 25, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Oct 22, 2024 | SC 13D/A | [Amend] Filing |
Sep 27, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |